ICFL 2019, Berlin - Program


Thursday, 27 June 2019

16:00 – 17:20

Welcome Address

Opening Session

Rifaat Safadi, Hadassah Hebrew University, Israel
Quentin Anstee, Newcastle University, UK

Keynote Lecture:

  • What is NAFLD - NASH and How it is Defined?

       Jean-Francois Dufour, University of Bern, Switzerland

  • Global Epidemiology & Outcomes of the NAFLD

       Zobair Younossi, Inova Fairfax Hospital, USA

​17:20 – 18:20

Should I be Looking for NASH in My Clinic? 

PRO - Jerome Boursier, Angers University Hospital, France


CON - Mark Walker, Newcastle University, UK

Open Discussion and Vote

Networking Reception



Friday, 28 June 2019

08:00 – 08:45
Morning Networking
08:45 – 09:15


Arun Sanyal, Virginia Commonwealth University, USA

Keynote lecture: 

  • Biomarkers in NAFLD - If Not a Biopsy, What - and Why?

       Quentin Anstee, Newcastle University, UK

09:15 – 11:15






Session 1: What Tools Do We Have to Assess Disease Severity in NAFLD


Lawrence Serfaty, University of Strsbourg, France

Blood Tests


  • Routine Blood Tests and Simple Scores in NAFLD

       Salvatore Petta, University of Palermo, Italy

  • New Technologies: Metabolomics, Genomics & Collagen Biomarkers

       Detlef Schuppan, Institute of Translational Immunology, Germany

MRI and Ultrasound


  • How to Use Imaging to Evaluate NASH in the Clinic – Practical Approaches for Use in the Real World?

       Manuel Romero Gomez, Institute of Biomedicine of Seville, Spain

  • Ultrasound-Based Elastography Techniques: TE, ARFI & SSI

       Laurent Castera, University of Paris-VII, France

  • MR-Based Assessment of Inflammation and Fibrosis

       Stefan Neubauer, Oxford University, UK

Panel Discussion

11:15 – 11:45Coffee break, Exhibition & Poster Viewing

11:45 – 13:00










Session 2: Screening - How Should I Evaluate NASH in My Clinic?  


Manuel Romero GomezInstitute of Biomedicine of Seville, Spain


  • Gastro/ Hepatologist Perspective  

       Lawrence Serfaty, University of Strsbourg, France

  • Diabetоlogist Perspective

       Gianluca Perseghin, University of Milano-Bicocca, Italy


Case Presentation

Panel Discussion 

13:00 – 14:00

Lunch, Exhibition & Poster Viewing

14:00 – 15:25










Session 3: Treating the Metabolic Syndrome in Patients with NAFLD



Arun SanyalVirginia Commonwealth University, USA

Gianluca PerseghinUniversity of Milano-Bicocca, Italy

  • Medical Therapy for T2DM

       Michael Roden, German Center of Diabetology, Germany

  • Medical Therapy for Dyslipidaemia

       Dirk Muller-Wieland, Aachen University Hospital, Germany


Case Presentation:

Optimization of glucose control in a NASH patient with type 2 diabetes

Sabine KahlGerman Diabetes Center, Germany

Panel Discussion

15:25 – 15:55
Coffee Break, Exhibition & Poster Viewing

15:55 – 17:45








Session 4: Treating NAFLD in Patients with the Metabolic Syndrome: Current Options


  • Dietary Management

       Shira Zelber Sagi, Tel Aviv Medical Center, and School of Public oooHealth, the University of Haifa, Israel

  • Alcohol in NAFLD: An Oxymoron or an Important Cofactor?

       Philip Newsome, University of Birmingham, UK

  • Current Available Pharmacological Therapeutic Options for NAFLD Using Drugs Available Today

       Kris Kowdley, Swedish Medical Center, USA

  • Bariatric Surgery for NAFLD

       Sebastian Mueller, University of Heidelberg, Germany


Case Presentation

Panel Discussion

17:45 – 19:15
Poster presentation & Reception


Saturday, 29 June 2019

08:00 – 08:30
Morning Networking

08:30 – 10:30




Session 5: Therapeutics Horizon Scanning: Treating NAFLD Tomorrow


Michael RodenGerman Center of Diabetology, Germany

Elisabetta BugianesiUniversity of Turin, Italy


Keynote Lecture:

  • NAFLD Pathophysiology: Targets for Novel Treatments

       Frank Tacke, Charité University, Berlin, Germany

Drug Targets in Phase 2/3 Trials – Evidence Base and Status Update


  • Bile Acid Signaling Pathways (FXR/FGF19)  

       Michael Trauner, Medical University of Vienna, Austria

  • Metabolic Pathways: Insulin Signaling, PPARs, THRb 2

       Rifaat SafadiHadassah Hebrew University, Israel

  • Trials Targeting Fibrosis

       Jörn Schattenberg, University Medical Center Mainz, Germany


Panel Discussion

10:30 – 11:00
Coffee Break, Exhibition & Poster Viewing

11:00 – 12:30










Session 6: Drug Development Overview & Clinical Pharmacology in Practice


Shira Zelber Sagi, Tel Aviv Medical Center, and School of Public Health, the University of Haifa, Israel

Jörn Schattenberg, University Medical Center Mainz, Germany


Keynote Lecture:

  • Why Too Many Strategies are Failing and do not Continue?

       Arun Sanyal, Virginia Commonwealth University, USA

  • DILI in NAFLD: How to Assess if a NASH Drug is Causing Liver Injury

       Guru Aithal, Nottingham University, UK


Panel Discussion 

12:30 – 14:15
Lunch Break, Exhibition & Poster Viewing

14:15 – 16:00


Session 7: NAFLD & Malignancy


Stefan ZeuzemGoethe University Hospital, Germany

Frank TackeCharité University, Berlin, Germany


  • Mechanisms of Obesity and NASH Related Carcinogenesis 

       Mathias Heikenwalder, German Cancer Research Center, Germany

  • HCC Surveillance in NAFLD – Who, How and Should You?

       Helen Reeves, Newcastle University, UK

  • Extra-Hepatic Malignancies in NAFLD

       Elisabetta Bugianessi, University of Turin, Italy


Case Presentation:

NASH patient with fibrosis F2 that developed HCC. Steatohepatitic variant of hepatocellular carcinoma that has interesting immunohistochemistry analysis and progression

Claudia P Oliveira, University of Sao Paulo, Brazil

Panel Discussion 

16:00 – 16:30
Summary & Closing Remarks

Keep Me Updated

​​​ ​​​​​ ​​​​​ ​​​​​